6d87

Publication Abstract from PubMed

The p85alpha protein regulates flux through the PI3K/PTEN signaling pathway, and also controls receptor trafficking via regulation of Rab-family GTPases. In this report, we determined the impact of several cancer patient-derived p85alpha mutations located within the N-terminal domains of p85alpha previously shown to bind PTEN and Rab5, and regulate their respective functions. One p85alpha mutation, L30F, significantly reduced the steady state binding to PTEN, yet enhanced the stimulation of PTEN lipid phosphatase activity. Three other p85alpha mutations (E137K, K288Q, E297K) also altered the regulation of PTEN catalytic activity. In contrast, many p85alpha mutations reduced the binding to Rab5 (L30F, I69L, I82F, I177N, E217K), and several impacted the GAP activity of p85alpha towards Rab5 (E137K, I177N, E217K, E297K). We determined the crystal structure of several of these p85alpha BH domain mutants (E137K, E217K, R262T E297K) for bovine p85alpha BH and found that the mutations did not alter the overall domain structure. Thus, several p85alpha mutations found in human cancers may deregulate PTEN and/or Rab5 regulated pathways to contribute to oncogenesis. We also engineered several experimental mutations within the p85alpha BH domain and identified L191 and V263 as important for both binding and regulation of Rab5 activity.

Patient-derived mutations within the N-terminal domains of p85alpha impact PTEN or Rab5 binding and regulation.,Mellor P, Marshall JDS, Ruan X, Whitecross DE, Ross RL, Knowles MA, Moore SA, Anderson DH Sci Rep. 2018 May 8;8(1):7108. doi: 10.1038/s41598-018-25487-5. PMID:29740032^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.